31.30
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Citi on Harmony (HRMY): 'FDA Denies Short Seller Citizens' Petition to Remove Wakix from the Market, Ending ... - StreetInsider.com
StreetInsider.com
Harmony Biosciences Says FDA Denies Short Seller Claims Over Narcolepsy Drug Safety - MarketWatch
MarketWatch
Harmony Biosciences (HRMY) Acknowledges FDA Action Denying The Citizen Petition For Wakix - StreetInsider.com
StreetInsider.com
Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for ... - Marketscreener.com
Marketscreener.com
Los Angeles Capital Management LLC Purchases 1076 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ ... - Defense World
Defense World
Harmony Biosciences (NASDAQ:HRMY) Receives “Buy” Rating from Needham & Company LLC - Defense World
Defense World
Harmony Biosciences maintains $56 target with Outperform rating - Investing.com India
Investing.com India
Harmony Biosciences maintains $56 target with Outperform rating By Investing.com - Investing.com
Investing.com
Harmony Biosciences maintains $56 target with Outperform rating By Investing.com - Investing.com UK
Investing.com UK
Wakix approval boosts Harmony Biosciences outlook By Investing.com - Investing.com Australia
Investing.com Australia
Wakix approval boosts Harmony Biosciences outlook By Investing.com - Investing.com Canada
Investing.com Canada
Wakix approval boosts Harmony Biosciences outlook - Investing.com India
Investing.com India
Silence Therapeutics receives $2 million from Hansoh Pharma By Investing.com - Investing.com
Investing.com
Harmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Needham & Company LLC - MarketBeat
MarketBeat
Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy ... - StreetInsider.com
StreetInsider.com
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX ... - PR Newswire
PR Newswire
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX in Pediatric Patients with ... - Marketscreener.com
Marketscreener.com
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $28.81 - Defense World
Defense World
Citigroup Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN
MSN
(HRMY) Long Term Investment Analysis - Stock Traders Daily
Stock Traders Daily
Harmony Bio gains as Citi starts at Buy on risk-reward setup - MSN
MSN
Harmony Biosciences (NASDAQ:HRMY) Receives New Coverage from Analysts at Citigroup - MarketBeat
MarketBeat
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts - Markets Insider
Markets Insider
Harmony Biosciences (NASDAQ:HRMY) Coverage Initiated at Citigroup - Defense World
Defense World
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts - Harmony Biosciences (NASDAQ ... - Benzinga
Benzinga
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $28.81 - MarketBeat
MarketBeat
Harmony Bio stock gains as Citi starts at Buy(NASDAQ:HRMY) - Seeking Alpha
Seeking Alpha
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains? - Yahoo Finance
Yahoo Finance
Citi sets Harmony Biosciences stock to buy with $48 target By Investing.com - Investing.com
Investing.com
Citigroup Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy Recommendation - MSN
MSN
Citi sets Harmony Biosciences stock to buy with $48 target By Investing.com - Investing.com
Investing.com
Harmony Biosciences Holdings Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
The InvestChronicle
Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S ... - Yahoo Finance
Yahoo Finance
Brokerages Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $40.63 - Defense World
Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Defense World
Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 - MyChesCo
MyChesCo
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Boosted by Campbell & CO Investment Adviser LLC - Defense World
Defense World
Harmony Biosciences Presents Promising Data on Pitolisant for Myotonic Dystrophy Type 1 - MyChesCo
MyChesCo
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Simply Wall St
Simply Wall St
Franklin Resources Inc. Acquires New Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
MarketBeat
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Has Fared Decently: Is the Market Following Strong ... - Yahoo Canada Sports
Yahoo Canada Sports
Franklin Resources Inc. Acquires Shares of 27136 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Defense World
Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy - Seeking Alpha
Seeking Alpha
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Quantisnow
Quantisnow
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Marketscreener.com
Marketscreener.com
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - PR Newswire
PR Newswire
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - PR Newswire
PR Newswire
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE ... - Quantisnow
Quantisnow
Kapitalisierung:
|
Volumen (24h):